Category: Research/Reports

Drug Industry-funded Think Tank Raises Questions About 340B Hospitals’ Charity Care

August 22, 2024 Shannon Young, Associate Editor/Senior Writer Views

The Pioneer Institute for Public Policy Research compared 29 financially strong 340B hospitals/health systems’ performance on charity care in an Aug. 19 brief.

More transparency surrounding 340B hospital operations is needed to ensure drug discount savings are being used to improve patient care, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

After Failing To Disclose Conflict of Interest, JAMA Issues Correction to Piece Calling for Increased 340B Oversight and Transparency

August 13, 2024 Bella Czajkowski, National Correspondent Views

JAMA corrected an opinion piece on the 340B program to disclose one author's drug industry ties, shortly after 340B Report reported on the omission.

Two weeks after publishing an opinion piece that called for increased 340B program oversight and provider transparency, JAMA issued a [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Two Researchers Call For More 340B Transparency, but JAMA Fails to Disclose Glaring Conflict of Interest

August 6, 2024 Bella Czajkowski, National Correspondent Views

Two researchers authored a recent JAMA opinion piece calling for significant 340B reforms including asking Congress to consider limiting the program to low-income patients.

A recent opinion piece published in JAMA is calling for significant reforms to the 340B program, including more provider transparency, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Study Finds Oncology Markups at 340B Pediatric Hospitals; AHA Slams Study and Funder

July 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

New research looked at the prices 340B-enrolled pediatric hospitals charged for pediatric oncology drugs.

The rates 340B pediatric hospitals negotiate with payers for new pediatric oncology drugs often exceed a medication’s average sale price, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

IRA Could ‘Crush the 340B Margin,’ Force Transparency into Program, Says Adam Fein of Drug Channels

June 25, 2024 William Newton, Associate Editor/Senior Writer Views

Adam Fein, Ph.D., president of Drug Channels Institute, hosted a June 21 webinar that discussed the IRA's interaction with the 340B program.

The Inflation Reduction Act (IRA) may reduce 340B margins for certain high-cost drugs and drive more transparency into the program, an influential pharmaceutical supply chain analyst who has been a frequent 340B critic told an audience of stakeholders late last

…

CBO Analysts Say Drug Spending Through 340B Grew 19% Annually From 2010 to 2021, 340B Champion Points Finger at Drug Industry

June 21, 2024 Shannon Young, Associate Editor/Senior Writer Views

Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by 2021—a 19% annual increase—according to preliminary Congressional Budget Office estimates released this week.

Spending on pharmaceuticals in the 340B drug discount program went from nearly $7 billion in 2010 to $44 billion by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Reform Could Generate Federal Savings, Says Consulting Firm That Has Conducted 340B Studies for Pharma Friendly Groups

June 11, 2024 Rich Daly, Editor in Chief Views

Avalere's Milena Sullivan told 340B Report that it's important to understand "the impact 340B reform could have on federal spending."

A federal legislative overhaul of the 340B program could provide Medicare savings for the federal government, according to a review [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Hospitals Prescribe Part D Drugs to a Much Higher Share of Vulnerable Populations, Says Hospital-Backed Report

May 23, 2024 Shannon Young, Associate Editor/Senior Writer Views

A hospital-funded study found 340B hospitals prescribe a higher share of Medicare Part D drugs to a higher share of vulnerable patients.

Medicare Part D beneficiaries who received retail and specialty drugs from prescribers at 340B disproportionate share hospitals (DSH) were more [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading

May 21, 2024 Rich Daly, Editor in Chief Views

A PhRMA funded report found that 340B drugs grew to 18% of total outpatient branded drug sales in 2022. The figures were criticized by 340B providers and others as misleading.

340B drugs have steadily increased as a share of U.S. branded outpatient pharmaceutical sales and reached 18% of the total [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds

May 16, 2024 Shannon Young, Associate Editor/Senior Writer Views

Analysts from IQVIA found that 340B wholesale acquisition cost sales increased by 17% from 2022 to 2023.

The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live